The international team of researchers combined lab-based experiments and epidemiology of vaccine breakthrough infections, showing that the Delta variant is better at replicating and spreading than other commonly-observed variants.
Poonawalla said the price will be around USD 5-6 per dose with an MRP of around Rs 1,000 for the two necessary doses.
Like the UK variant identified earlier, the new variant of the novel coronavirus is also driving a massive resurgence of the disease in South Africa, with experts warning the country is probably facing a much larger second wave.
In a report submitted Monday to Rajya Sabha chairman and Vice President M Venkaiah Naidu, the Parliamentary Standing Committee on Home Affairs also said there was a need for a comprehensive public health law to keep a tab on private hospitals and check black-marketing of medicines.
Communications between the USTR and the world's most powerful pharmaceutical and trade lobbying groups reveal that many raised concerns about India's push to exempt Covid vaccines from intellectual property.
The Department of Health and Social Care said a total of 81,959,398 doses of COVID vaccines have been administered in the UK, with 46,227,101 people receiving a first dose (87.8 per cent) and 35,732,297 people receiving both doses (67.8 per cent).
"The concrete actions are a stern indication that Government of India is making all out efforts to increase vaccine production in the country as well as attracting foreign vaccine manufacturers to supply the required vaccine doses for national Covid vaccination programme," the ministry in a statement.
According to the sources, there are limited prospects of J&J exporting its vaccine from the US to other countries in the near future and the "entire production" at the BE facilities in India, beginning July/August, will be handed over to the pharma giant under a contract between the companies.
The Johnson and Johnson and Sputnik vaccines should be approved now, as should the Pfizer and Moderna ones, suggests Naushad Forbes. Leave it to the companies to figure out how to put in place the right chilling infrastructure. Don't let a lack of approvals deprive the country of availability, suggests Naushad Forbes.
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
Companies which have been dropped from the list include Tata Motors, Hindustan Unilever, MRF, Glaxo SmithKline Consumer Healthcare, Pfizer, Dr Reddy's Labs, Glenmark Pharmaceuticals, HDFC and Kotak Mahindra Bank
Popular antacid Mucaine Gel, manufactured by Pfizer's subsidiary Wyeth Laboratories, was also found laced with the heavy metals as well as cadmium.
Health Minister Harsh Vardhan said the COVID-19 vaccine will be available in the next few months and it is estimated that by July-August 400-500 million doses will be made available for 25-30 crore people.
The primary objective was to get the adult vaccine as children rarely have a severe form of the disease. Once schools reopen, the demand for vaccines for children under 12 may soar.
The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.
Asserting that India is on track to vaccinate its entire adult population by December, top officials on Monday said a blueprint is in place to ensure a total supply of 187.2 crore doses by the year-end that would be enough for the country's 94 crore 18-plus population.
The Biden administration had been under pressure to send the excess COVID-19 vaccines with the US to nations like India, which are facing severe vaccine shortages.
To enable large-scale vaccine studies to take place across the UK, the aim is to get 500,000 people signed up by October, which is considered vital in the fight against coronavirus.
There is a process to be followed for EUL and pre-qualification of vaccines under which a company has to complete phase 3 trials and submit the whole data to the regulatory department of WHO which is examined by an expert advisory group," Swaminathan said.
Will syringe shortage puncture India's Covid vaccine plans?
The women who made India proud in Tokyo are set to be the Independence Day mascots. Invite from the PM has already gone out to these achievers to be guests of honour on August 15.
'You will not have a vaccine for everyone initially.'
It is in no way a government of the economic Right. The Right is limited to religion and nationalism. The rest is as Left as the Congress or any other party, observes Shekhar Gupta.
A technical advisory group of the UN health agency which met on Tuesday has sought "additional clarifications" from Bharat Biotech for Covaxin to conduct a final "risk-benefit assessment" for Emergency Use Listing of the vaccine.
Vaccines Covishield and Covaxin work against SARS-CoV-2 variants Alpha, Beta, Gamma and Delta, while effectiveness tests against the Delta Plus variant is ongoing, the government said.
In a development that might result in India's leading drug maker Ranbaxy selling a generic version of Pfizer's blockbuster drug Lipitor sooner than expected in the US market, the United States patent office has made an initial rejection of Pfizer's claim on the basic patent on Lipitor.
As many as 721,469 appointments were made through the national booking service on Friday -- the day of the announcement -- at an average of more than eight every second. To cope with demand, the NHS said it is using stadiums and football grounds as giant vaccination centres.
In a boost to Ranbaxy in its ongoing litigation over anti-cholesterol drug Lipitor (atorvastatin) against Pfizer, a Norway court today ruled that four of the US pharma giant's patents were either invalid or not infringed by the Indian company.
Giuliani, 76, has been taken to the Medstar Georgetown University Hospital in Washington DC, according to US media reports.
The Serum Institute of India, Bharat Biotech and Pfizer have applied to the DCGI seeking emergency use authorisation for their COVID-19 vaccine candidates and are awaiting approval.
The Serum Institute of India has stockpiled 40 mn-50 mn doses and is adding more every week. Most of these will come to India.
An important focus of the dry run will be on management of any possible adverse events following immunisation.
He also said that there were around 620 cases of black fungus or mucormycosis in the city, but there is a shortage of Amphotericin-B injections used in its treatment.
The data leak obtained by 'The Australian' newspaper has revealed how the alleged CPC members are employed with some of the world's biggest corporations in the areas of defence, banks and pharmaceutical giants manufacturing coronavirus vaccines.
A longer shelf life is critical, given many makers have started manufacturing vaccines and stockpiling them, so as to make them available in the market immediately after approval, reports Sohini Das.
The vaccine would be first made available to the vulnerable population and eventually, it would be available in the private market for all.
The Medicines and Healthcare Products Regulatory Agency said in its latest Yellow Card monitoring of the coronavirus vaccine programme this week that of the 18.1 million people who had the Oxford vaccine in the UK, 30 people developed blood clots and seven had died as of March 24.
Country's biggest drug maker, Ranbaxy Laboratories Ltd on Wednesday said a US Appeals Court has ruled in its favour in the patent infringement case with Pfizer for cholesterol-lowering drug Atorvastatin (Lipitor).
The phase 3 trial is being implemented as part of Operation Warp Speed, a multi-agency collaboration led by the US Health and Human Services, which aims at accelerating the development and manufacturing of medical countermeasures for COVID-19 and delivering 300 million doses of an effective vaccine by January 2021.
A US court has ruled against Ranbaxy in its case for non-infringement and invalidation of two patents of its competitor Pfizer
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances